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Background: Lung cancer is a devastating disease with limited treatment options.
Many lung cancers have changes in their microenvironment including upregulation of
the extracellular matrix glycosaminoglycan, hyaluronan (HA), which we have previously
demonstrated can regulate the activity of the extracellular serine protease, hyaluronan
binding protein 2 (HABP2). This study examined the functional role of HABP2 on
HA-mediated human lung cancer dynamics.
Methods: Immunohistochemical analysis was performed on lung cancer patient samples
using anti-HABP2 antibody. Stable control, shRNA, and HABP2 overexpressing human
lung adenocarcinoma cells were evaluated using immunoblot analysis, migration, extrava-
sation, and urokinase plasminogen activator (uPA) activation assays with or without
high-molecular weight HA or low-molecular weight HA (LMW-HA). In human lung cancer
xenograft models, primary tumor growth rates and lung metastasis were analyzed using
consecutive tumor volume measurements and nestin immunoreactivity in nude mouse
lungs.
Results: We provide evidence that HABP2 is an important regulator of lung cancer
progression. HABP2 expression was increased in several subtypes of patient non-small
cell lung cancer samples. Further, HABP2 overexpression increased LMW-HA-induced
uPA activation, migration, and extravasation in human lung adenocarcinoma cells. In vivo,
overexpression of HABP2 in human lung adenocarcinoma cells increased primary tumor
growth rates in nudemice by ~2-fold and lungmetastasis by ~10-fold compared to vector
control cells (n=5/condition).
Conclusion: Our data suggest a possible direct effect of HABP2 on uPA activation
and lung cancer progression. Our observations suggest that exploration of HABP2 in
non-small cell lung carcinoma merits further study both as a diagnostic and therapeutic
option.
Keywords: HABP2, hyaluronan, urokinase plasminogen activator, non-small cell lung cancer, transendothelial
extravasation
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Introduction
Effective therapeutic strategies for lung cancer, the leading cause
of cancer-associated mortality worldwide, are extremely limited
exemplifying the need for novel therapeutic targets (1, 2). Previous
reports have demonstrated that the extracellular serine protease,
hyaluronan binding protein 2 (HABP2), is upregulated in several
types of humannon-small cell lung cancer (NSCLC) (3). However,
the functional consequences of HABP2 overexpression in NSCLC
are poorly defined. HABP2, also called factor VII activating pro-
tease (FSAP), is an extracellular serine protease involved in the
extrinsic pathway of blood coagulation via activation of factor
VII and fibrinolysis via activation of pro-urokinase type plas-
minogen activator (pro-uPA) (4, 5). HABP2 has been implicated
in several disease processes including atherosclerosis and deep
venous thrombosis (4, 6). Initially expressed in a single amino
acid chain proenzymatic form, HABP2 undergoes autocatalytic
cleavage upon binding of a ligand (7). Originally isolated based
on its affinity for hyaluronan (HA) (8), HABP2 is capable of being
activated by variety of polyanions including heparin and nucleic
acids (9, 10). The fully mature enzyme consists of trypsin-like
catalytic domain, linked via disulfide bond to the kringle domain
and three epidermal growth factor (EGF)-like domains (4, 5). The
second and third EGF-like domains form the polyanion binding
domain (PABD) (10). We have previously reported that HABP2 is
upregulated in the pulmonary vasculature with acute lung injury
(ALI) and promotes disruption of vascular integrity (11).
The major non-sulfated glycosaminoglycan in most tissues,
hyaluronan (HA), plays an important role in cancer progression
(12–17). HA is composed of a linear repeat of disaccharide units
consisting of -glucuronic acid and N-acetylglucosamine (18–
21). The major form of HA in vivo, high-molecular weight HA
(HMW-HA), has a molecular weight >1million Da (17). HMW-
HA exhibits a random coil structure that can expand in aqueous
solutions (22). During disease states, HMW-HA can be cleaved to
low-molecular weightHA (LMW-HA) via hyaluronidase enzymes
and reactive oxygen species (ROS) (23–29). We have previously
reported that HMW-HA inhibits, while LWM-HA enhances,
HABP2 enzymatic activity (11).
In this study, we investigated the effects of stable silencing or
overexpression of HABP2 onHMW-HA and LMW-HA-regulated
human NSCLC cell migration, extravasation, tumor growth, and
metastasis. Here, we present evidence of a role for HABP2 in the
regulation of urokinase plasminogen activator (uPA) activation
during lung cancer progression. Further, through the use of tumor
xenograft models, our results suggest a possible therapeutic role
for HABP2 antagonism on cancer growth and metastasis, which
merits further research.
Materials and Methods
Cell Culture and Reagents
Human NSCLC cell lines A549, SK-LU-1, H1703, H358, H1993,
H661, SW1573, H522, H226, H1437, H1838, H1975, H2170,
and non-cancerous BEAS-2B were obtained from ATCC (Walk-
ersville, MD, USA) and cultured in Roswell Park Memorial Insti-
tute complete medium (Cambrex, East Rutherford, NJ, USA)
at 37°C in a humidified atmosphere of 5% CO2, 95% air, with
passages 6–10 used for experimentation. Unless otherwise spec-
ified, reagents were obtained from Sigma (St. Louis, MO, USA).
UK122 was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Reagents for SDS-PAGE electrophoresis were
purchased from Bio-Rad (Richmond, CA, USA) and Immobilon-
P transfer membrane was purchased from Millipore (Millipore
Corp., Bedford, MA, USA). Mouse anti-HABP2 antibody was
purchased from Novus Biologicals (Littleton, CO, USA). Mouse
anti-human nestin antibody that does not react with mouse or
rat nestin (clone 10C2) was purchased from Millipore (Bedford,
MA, USA). Mouse anti-β-actin antibody was purchased from
Sigma (St. Louis, MO, USA). Secondary horseradish peroxidase-
labeled antibodies were purchased from Amersham Biosciences
(Piscataway, NJ, USA).
Immunoblotting
Immunoblotting was performed, as we have previously described
(24, 30). Cellular materials from treated or untreated human
NSCLC cells were incubated with lysis buffer [50mM HEPES
(pH 7.5), 150mM NaCl, 20mM MgCl2, 1% Triton X-100,
0.1% SDS, 0.4mM Na3VO4, 40mM NaF, 50µM okadaic acid,
0.2mM phenylmethylsulfonyl fluoride, and 1:250 dilution of
Calbiochem protease inhibitor mixture 3). The samples were
then run on SDS-PAGE in 4–15% polyacrylamide gels, trans-
ferred onto Immobilon™membranes, and developedwith specific
primary and secondary antibodies. Visualization of immunore-
active bands was achieved using enhanced chemiluminescence
(AmershamBiosciences, Piscataway, NJ, USA). In some instances,
immunoreactive bands were quantitated using computer-assisted
densitometry.
Preparation of HMW-HA and LMW-HA
High-molecular weight HA and LMW-HA were prepared similar
to that as we have previously described (24). For HMW-HA,
500mg of hyaluronan sodium salt from Streptococcus zooepi-
demicus was centrifuged in an Ultrafree-MC™Millipore 100 kDa
MW cutoff filter and the upper (non-flow-through) portion was
kept and resuspended in PBS, pH= 7.4. For LMW-HA, 500mg
of hyaluronan sodium salt from S. zooepidemicus was digested
with 20,000U of bovine testicular hyaluronidase (Type VI-S),
lyophilized powder, 3,000–15,000U/mg (Sigma, H3631) in diges-
tion buffer (0.1M sodium acetate, pH 5.4, 0.15M NaCl) for 24 h,
and the reaction stopped with 10% trichloroacetic acid. The
resulting solution was centrifuged in an Ultrafree-MC™Millipore
5 kDa MW cutoff filter and the flow through was dialyzed against
distilled water for 24 h at 4°C in 500Da cutoff Spectra-Por tubing
(Pierce-Warriner, Chester, UK). HMW-HA and LMW-HA were
quantitated using an ELISA-like competitive binding assay with
a known amount of fixed HA and biotintylated HA-binding pep-
tide (HABP) as the indicator (Echelon Inc.). HA solutions were
filtrated through 0.22µm filters and kept in sterile tubes. In some
cases, both LMW-HA andHMW-HAwere subject to boiling, pro-
teinase K (50µg/ml) digestion, hyaluronidase SD digestion [Strep-
tococcus dysgalactiae, NorthStar Bioproducts Associates of Cape
Cod Inc., East Falmouth, MA, USA (100741-1A), 100mU/ml
utilized], or addition of boiled (inactivated) hyaluronidase SD to
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test for possible protein/lipid contaminants. To test for endo-
toxin contamination of HA, a lipopolysaccharides (LPS) BioAssay
ELISA kit (USBiological Life Sciences) was utilized. LMW-HA
with HA standards (Sigma and Enzo Life Sciences) were run on
4–20% Tris/Borate/EDTA (TBE) gels and stained with Stains-All
(Sigma) to confirm LMW-HA purity and size.
Stable Vector Control and HABP2
Overexpression in NSCLC Cells
The pCMV6-XL5 human HABP2 overexpression vector and vec-
tor control (pCMV6-AC-GFP)were purchased fromOrigene. SK-
LU-1 cells were transfected with vectors using FuGENE HD™ as
the transfection reagent (Roche Applied Sciences) according to
the protocol provided by Roche, as we have previously described
(31). Cells (~40% confluent) are serum-starved for 1 h followed
by incubated with vectors for 6 h in serum-free media. Serum-
containing media was then added (10% serum final concentra-
tion) for 42 h and G418 selection reagent was added. Overexpres-
sion was confirmed by immunoblot analysis with anti-HABP2
antibody (Novus Biologicals, Littleton, CO, USA).
Stable Control and HABP2 Small Hairpin RNA
Transfection in Human NSCLC Cells
Stable Control and HABP2 shRNA (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) were stably transfected into SK-LU-1 cells,
as we have previously described (32). Cells (~40% confluent)
were serum-starved for 1 h followed by incubated with shRNA
for 6 h in serum-free media. Serum-containing media was then
added (10% serum final concentration) for 42 h and puromycin
selection reagent was added. Inhibition of protein expression was
confirmed by immunoblot analysis with anti-HABP2 antibody
(Novus Biologicals, Littleton, CO, USA).
uPA Activation Assay
Activation of uPA was quantitated using an uPA Activity Assay
Kit (Chemicon International, Temecula, CA, USA). Briefly,
serum-free media from control, HABP2 silenced or HABP2 over-
expressing SK-LU-1 cells treated with either 100 nM HMW-HA
or LMW-HA for 6 h was added to a 96 well microplate and a
chromogenic substrate, which is cleaved by active uPA was added.
The resulting colorimetric assay was read at an optical density of
405 nm in a microplate reader. Each assay was set up in triplicate
and repeated at least five times.
Human NSCLC Cell Migration Assay
Measurement of in vitro NSCLC cell migration was performed,
as we have previously described (30). Twenty-four transwell units
with 8µm pore size (Millipore, Billerica, MA, USA) were used
for monitoring in vitro cell migration. Control or HABP2 overex-
pressing cells (5 103 cells/well) were plated in the upper chamber
and incubated with 0.2ml of serum-free media containing either
vehicle (control), 100 nMLMW-HAor 100 nMHMW-HAwith or
without 1 h pretreatment with 1µM of the uPA inhibitor UK122
andmedia with serumwas added to the lower chamber. Cells were
allowed tomigrate through the pores for 18 h.Cells from the upper
and lower chamber were quantitated using the CellTiter96™MTS
assay (Promega, San Luis Obispo, CA, USA) and read at 492 nm.
Percent migration was defined as the number of cells in the lower
chamber divided by the number of cells in both the upper and
lower chamber. Each assay was set up in triplicate and repeated at
least five times.
Cell Motion Analysis on Imaris
TheOlympus LCV110UVivaView was used for long-term live cell
imaging. Cells were recorded for 10 s every 10min for 24 h. After
record, images were processed and converted into a TIFF format
using ImageJ. Stacks of high-resolution images were converted to
AVI video as the full trace of the records. To analyze cell track
and velocity, imaging data were processed with Imaris (Bitplane).
Imaris spot detection module and Brownian algorithm were used
to calculate cell coordinates (mean position) over time. Due to cell
clustering, some compromises were made between the number
of cells tracked and the quality of the traces. The results of the
tracking were manually edited to correct or remove errant traces.
The data generated by Imaris were then exported to an Excel
worksheet and analyzed to calculate cell track and speed. Ten cells
per condition were utilized.
Transendothelial Extravasation Assay
The ability of NSCLC cells to invade though a layer of endothe-
lial cells (ECs) was quantified using transendothelial monolayer
resistance measurements using an electrical substrate-impedence
sensing system (Applied Biophysics, Troy, NY, USA), as we have
previously described (31). Briefly, human pulmonary microvas-
cular ECs were grown to confluence on gold plated microelec-
trodes connected to a phase-sensitive lock-in amplifier. Stable
vector control, HABP2 silenced, or HABP2 overexpressing SK-
LU-1 cells (5 103 cells/well) untreated or treated with 1µM
UK122 or 5% serum media only control were added to the con-
fluent endothelial monolayers on the electrodes. The electrical
substrate-impedence sensing system allows for continuous mea-
surement of the endothelial monolayer resistance as the SK-LU-1
cells attach and begin to invade into the monolayer. A decrease
in transendothelial monolayer resistance indicates a disrupted
endothelial monolayer barrier via transendothelial extravasation
ofNSCLC cells. Resistance readingswere normalized relative to an
undisturbed confluent endothelial monolayer. Experiments were
performed in triplicate with five independent experiments.
Human NSCLC Xenograft Studies in Nude Mice
All animal procedures were carried out in accordance with the
guidelines provided by the Institutional Animal Care and Use
Committee of the University of Chicago (Chicago, IL, USA).
All mice were 8- to 12-week-old males obtained from Harlan
Laboratories (Indianapolis, IN, USA). At the end of each exper-
iment, lungs and primary tumors were collected, fixed in forma-
lin, and embedded in paraffin or solubilized in extraction buffer
for immunoblot analysis. 1.0 106 stable vector control, HABP2
silenced, or HABP2 overexpressing SK-LU-1 cells were mixed
with Matrigel supplemented with 100 ng/ml HMW-HA or LMW-
HA (conditions we previously established to produce optimal SK-
LU-1 tumor growth) and injected subcutaneously into the flank
of Ncr-nude mice. Tumor nodules were measured regularly for
30 days using calipers, and tumor volume VT (cubic millimeter)
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was calculated using the ellipsoid formula A2B π/6, where A
represents the smaller diameter (33). Fivemice per conditionwere
utilized.
Quantification of Lung Metastasis
To characterize metastasis from primary tumors growing in
mouse hind flank, lungs from vector control, HABP2 silenced,
or HABP2 overexpressing SK-LU-1 hind flank-injectedmice were
solubilized in extraction buffer [50mMHEPES (pH 7.5), 150mM
NaCl, 20mM MgCl2, 1% Triton X-100, 0.2% SDS, 0.4mM
Na3VO4, 40mMNaF, 50µMokadaic acid, 0.2mMphenylmethyl-
sulfonyl fluoride, 1:250 dilution of Calbiochem protease inhibitor
mixture 3] with sonication. The resulting material was run
on SDS-PAGE in 4–15% polyacrylamide gels, transferred onto
Immobilon™ membranes, and developed with specific primary
and secondary antibodies. An anti-human nestin antibody (clone
10C2, Millipore) that does not react with mouse or rat nestin was
used for quantitation of SK-LU-1 cell metastasis to the lung (32).
Five mice per condition were utilized.
Human Lung Immunohistochemistry
Immunohistochemical analysis was performed on human tis-
sue microarrays (TMA, RayBiotech, Inc., Norcross, GA, USA).
For antigen retrieval, sections were heated in Tris-EDTA buffer
(pH= 9) for 10min and incubated for 1 h at room temperature
with mouse anti-HABP2 antibody (1:100) (Novus Biologicals,
Littleton, CO, USA). This was followed by 30min incubation with
goat anti-mouse HRP-conjugated IgG (EnVisionTM+, Dako).
Slides were developed for 5min with 3,30-diaminobenzidene
chromogen and counterstained with hematoxylin. Five samples
per condition were utilized.
Quantification of HABP2 Expression in Human
Lung Samples
Hyaluronan binding protein 2 quantification in human lung can-
cer samples was performed, as we have previously described (32).
HABP2 immunohistochemical staining was performed on tissue
microarrays (TMA, RayBiotech, Inc., Norcross, GA, USA) con-
taining 10 cases of human bronchioloalveolar carcinoma (BAC),
adenocarcinoma (Adeno) or squamous cell carcinoma (SCC) lung
cancer, and adjacent normal tissue. The microscopic images of
each slide were scanned and analyzed using Chromavision Auto-
mated Cellular Imaging System (ACIS, Clarient, Aliso Viejo, CA,
USA) in a digital format that accounts for all individual micro-
scopic fields. Areas of interest were outlined and the intensity was
quantified by the software and converted to a score over a set of
defined parameters. Brown integrated optical density (IOD)/10µ2
was used as a unit of measurement since IOD (intensity multi-
plied by brown area in squared micrometers). Five samples per
condition were utilized.
Statistical Analysis
Results are expressed as mean SD of five independent experi-
ments. For data analysis, experimental samples were compared to
controls by unpaired Student’s t-test. For multiple-group compar-
isons, a one-way variance analysis (ANOVA) and post hocmultiple
comparisons tests were used. Differences between groups were
considered statistically significant when p value was <0.05. All
statistical analyses were performed using the GraphPad Prism
program (GraphPad Software Inc., USA).
Results
Non-small cell lung cancer, which accounts for ~80% of all lung
cancers, is heterogeneous disease composed of several types,
including adenocarcinoma, BAC, SCC, adenosquamous carci-
noma, and large cell carcinoma (34, 35). We determined the
relative levels of HABP2 expression in human NSCLC cell lines
representing these various types and observed a 5- to 10-fold
increase in HABP2 expression is most cell lines relative to con-
trol non-cancerous BEAS-2B cells (see Figure 1A). These results
are consistent with previous published data indicating that the
HABP2 is upregulated in lung tissue from patients with NSCLC
(3). Due to differences in the loading controls, we performed
computer-assisted densitometry on the immunoreactive bands
that are graphically displayed in Figure 1B. We next examined
HABP2 expression in lung samples from patients with several
forms of NSCLC. Figure 1C shows the immunohistochemical
scoring of HABP2 in LTAC, lung tissue adjacent to cancer; CC,
lung carcinoid cancer; ADCC, lung adenocarcinoma; BAC, bron-
choalveolar carcinoma; SCC, lung small cell cancer; BC, breast
cancer (TMA slide from RayBiotech, Inc.) (32). While there was
considerable variability as indicated by the error bars possibly due
to our low sample size (N= 5/condition), we observed a trend
toward increased HABP2 expression in several types of NSCLC
compared to lung tissue adjacent to cancer.
To test the functional significance of HABP2 upregulation,
we generated stable vector control and HABP2 overexpressing
human SK-LU-1 lung adenocarcinoma cells.We chose the SK-LU-
1 cell line to study HABP2 overexpression based on its low-basal
metastatic potential (36). We observe robust HABP2 immunore-
activity in stable overexpressing HABP2 and significant silencing
of expression in shRNA treated SK-LU-1 cells compared to con-
trol (Figure 2A). Since there is an intimate relationship between
HABP2 and uPA often leading to reciprocal protease activation
(7), we next focused on measuring uPA activity, which has been
reported to contribute to lung cancer progression. We have previ-
ously reported that HMW-HA (the main form of HA in the body)
inhibits HABP2 activation while LMW-HA (generated in disease
states, such as cancer, by hyaluronidase enzymes and ROS) acti-
vates HABP2 activity (11), and therefore, we examined the roles of
HABP2 and HA on uPA activation in SK-LU-1 cells (Figure 2B).
Our results indicate that HABP2 overexpression promotes, while
HABP2 silencing inhibits basal uPA activity. In addition, LMW-
HA treatment enhances this activity, while HMW-HA addition
tends to inhibit uPA activation in SK-LU-1 cells. Considering the
low levels of uPA activity in HABP2 silenced cells, we focused
our consequent studies on comparing stable vector control and
HABP2 overexpressing SK-LU-1 functional analysis.
We next examinedHA- andHABP2-regulated SK-LU-1 human
lung adenocarcinoma cellmotion andmigration (Figure 3). Using
CellMotionAnalysis on Imaris (seeMaterials andMethods), indi-
vidual cell movement over the timewas analyzed (Figure 3A). Ten
cells for each treatment weremanually labeled. Spots were tracked
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FIGURE 1 | Hyaluronan binding protein 2 is upregulated in several human NSCLC cell lines and patient tumors.
(Continued)
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FIGURE 1 | Continued
(A) Immunoblot analysis using anti-HABP2 and anti-actin antibodies of cell
lysates from human adenosquamous carcinoma (A549), adenocarcinoma
(SKLU-1, H1703, H1993, H522, H1437, H1838, H1975), bronchioloalveolar
carcinoma (H358, SW1573), large cell carcinoma (H661), squamous cell
carcinoma (H226, H2170), and non-cancerous BEAS-2B cells. The arrow
indicates the position of HABP2. (B) Due to differences in the loading controls,
we performed computer-assisted densitometry on the immunoreactive bands
in (A). The results are graphically displayed as percent control (BEAS-2B)
HABP2 immunoreactivity divided by actin immunoreactivity with error
bars=SD. The single asterisks (*) refers to a statistically significant difference
(p<0.05) from control (BEAS-2B). (C) Representative immunohistochemical
(IHC) analysis of normal lung and lung tumor samples from patients indicating a
trend toward increased expression of HABP2 in lung carcinoid cancer (CC),
bronchioloalveolar carcinoma (BAC), adenocarcinoma (ADCC), squamous cell
carcinoma (SCC), and breast cancer (BC) compared to lung tissue adjacent to
cancer (LTAC). HABP2-specific brown staining intensity from five patient
samples per group were analyzed, as we have previously described.
FIGURE 2 | Low-molecular weight HA and HABP2 promote uPA
activation in human lung adenocarcinoma cells. (A) Immunoblot
analysis of control, HABP2 shRNA, and HABP2 overexpressing (O/E)
SK-LU-1 cells using anti-HABP2 and anti-actin antibodies. (B) Graphical
representation of uPA activation from media of treated SK-LU-1 cells.
Control, HABP2 shRNA, and HABP2 overexpressing cells were either
untreated or treated with 100 nM of either LMW-HA or HMW-HA for 6 h in
serum-free media. Media was then collected and analyzed using an uPA
Activity Assay Kit (Chemicon International, Temecula, CA, USA). The single
asterisks (*) refers to a statistically significant difference (p<0.05) from
control (100%). Each assay was set up in triplicate and repeated at least
five times.
over time and total maximal distance for all spots was recorded
for 24 h. Cellular track length was measured in microns. HABP2
overexpression or treatment with LMW-HA (but not HMW-
HA) significantly increased cellular track length (double asterisks)
compared to vector control, which were significantly inhibited by
the uPA antagonist UK122 (37) (single asterisks). We observed
similar results with SK-LU-1migration using 8µm transwell units
(seeMaterials andMethods) (Figure 3B) indicating that treatment
with LMW-HA and HABP2 overexpression significantly increase
SK-LU-1 cellmotion andmigration in an uPA-dependentmanner.
In order for many tumor cells to metastasize, they need to
breech the endothelium to enter the bloodstream (12). We tested
the in vitro ability of vector control and HABP2 overexpressing
SK-LU-1 cells to disrupt a confluent human pulmonarymicrovas-
cular ECmonolayer using an electrical substrate-impedence sens-
ing system, as we have previously described (31). This system
continuously measures endothelial monolayer resistance as the
SK-LU-1 cells attach and begin to invade into the monolayer. A
decrease in resistance indicates a disrupted endothelial monolayer
barrier via transendothelial extravasation of the NSCLC cells.
Figure 4 indicates HABP2 overexpressing SK-LU-1 cells have
increased extravasation properties compared to vector control
cells, which becomes apparent ~2–4 h after NSCLC cell addition
to the confluent endothelial monolayer. These effects are inhibited
by the uPA inhibitor UK122 (Figure 4B), results similar to our
in vitro cell motion and migration assays.
We next translated our in vitro results to an in vivo human
NSCLC xenograft model. Vector control, HABP2 silenced, and
HABP2 overexpressing SK-LU-1 cells were mixed with Matrigel
supplemented with 100 ng/ml HMW-HA or LMW-HA and were
injected into the hind flank of nude mice. Tumor volumes were
measured using calipers for 30 days (see Figure 5A) as described
in the Section “Materials and Methods.” HABP2 overexpressing
SK-LU-1 cells had ~2-fold increase in primary tumor growth
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FIGURE 3 | Low-molecular weight HA and HABP2 promote
uPA-dependent SK-LU-1 cell motion and migration. (A) Graphical
representation of cell motion as measured by cellular track length (micrometer)
from treated SK-LU-1 cells. Stable vector control or HABP2 overexpressing
SK-LU-1 cells were seeded (30103 cells/dish) to glass bottom dishes
(MatTek), either pretreated with vehicle or 1µM uPA inhibitor (UK122) for 1 h and
either no (control) or 100 nM of LMW-HA or HMW-HA was then added. Cells
were then processed for video recording for 24 h. Ten cells for each treatment
were manually labeled and cellular track length was then analyzed using Imaris
software. The single asterisks (*) represents a statistically significant difference
(p<0.05) from control (no UK122 addition). The double asterisks (**) represents
a statistically significant difference (p<0.05) from control (200 nm cellular track
length). Each assay was set up in triplicate and repeated at least five times.
(B) Graphical representation of the percent control migration of treated SK-LU-1
cells. Control or HABP2 overexpressing cells (5103 cells/well) were plated on
the upper chamber of 8µm transwell units and incubated with 0.2ml of
serum-free media containing either vehicle (control), 100 nM LMW-HA or
100 nM HMW-HA with or without 1 h pretreatment with 1µM of the uPA inhibitor
UK122 and media with serum was added to the lower chamber. Cells were
allowed to migrate through the pores for 18 h. Cells from the upper and lower
chamber were quantitated using the CellTiter96™ MTS assay (Promega, San
Luis Obispo, CA, USA) and read at 492 nm. Percent migration was defined as
the number of cells in the lower chamber divided by the number of cells in both
the upper and lower chamber. The single asterisks (*) represents a statistically
significant difference (p<0.05) from control (no UK122 addition). The double
asterisks (**) represents a statistically significant difference (p<0.05) from
control (100%). Each assay was set up in triplicate and repeated at least five
times.
rate compared to vector control cells (single asterisks). HABP2
silenced cells did not show a significant tumor size difference
from control. LMW-HA increased control (double asterisks) and
HABP2 overexpressing (triple asterisks) in a statistically signifi-
cant manner. In contrast, HMW-HA had little additional effect
on tumor growth.
Considering the differential growth rates of the primary tumors
in nude mice, we next examined the metastatic potential of
vector control andHABP2 overexpressing SK-LU-1 primary flank
tumors. These tumor cells tend to have low basalmetastatic poten-
tial (36). However, as time progresses and/or mutations arise, the
invasive properties of SK-LU-1 cells can increase (38, 39). Most
types of NSCLC express the protein marker nestin. In an attempt
to quantitate total SK-LU-1 cell metastasis to the mouse lung, we
utilized nestin immunoreactivity, as we and others have previously
described (31, 40–43). We quantitated lung metastasis using an
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FIGURE 4 | Hyaluronan binding protein 2 overexpression in human
lung adenocarcinoma cells promotes uPA-dependent
transendothelial extravasation. (A) Graphical representation of the ability
of vector control and HABP2 overexpressing (O/E) SK-LU-1 cells to disrupt a
confluent human pulmonary microvascular endothelial cell monolayer using
an electrical substrate-impedence sensing system, as we have previously
described. This system continuously measures endothelial monolayer
resistance as the SK-LU-1 cells attach and begin to invade into the
monolayer. A decrease in resistance indicates a disrupted endothelial
monolayer barrier via transendothelial extravasation of the NSCLC cells.
HABP2 overexpressing SK-LU-1 cells have increased extravasation
properties compared to vector control cells, which becomes apparent
~2–4 h after NSCLC cell addition (vertical green line) to the confluent
endothelial monolayer with five pooled-independent experiments repeated in
triplicate and error bars=SD. (B) Graphical representation of normalized
resistance at 20 h with vector control and HABP2 overexpressing (O/E)
SK-LU-1 cells with or without pretreatment of 1µM uPA inhibitor (UK122) for
1 h prior to addition to confluent human pulmonary microvascular endothelial
monolayers. The single asterisks (*) represents a statistically significant
difference (p<0.05) from control.
anti-human nestin antibody that does not react with mouse (31).
Figure 5B indicates robust nestin immunoreactivity in the lung
homogenates of HABP2 overexpressing but not vector control
or HABP2 silenced mice. Quantitation of nestin immunoreac-
tivity revealed ~10-fold increase in lung metastasis from HABP2
overexpressing primary tumors indicating the importance of this
molecule in lung cancer progression (Figure 5C).
Discussion
Based on the recent published data indicating HABP2 are
increased in lung cancer (3), this study investigated the functional
effects of HABP2 in human NSCLC cells both in vitro and in vivo.
We observed that HABP2 overexpression in SK-LU-1 human
NSCLC cells increased cell motion, migration, transendothelial
extravasation, tumor growth and metastasis, and activation of
the extracellular serine protease, uPA, implicated in cancer pro-
gression. In addition, LMW-HA enhances these in vitro activities
and increases control and HABP2 overexpressing primary tumor
volumes in nude mice. In contrast, HMW-HA either inhibited or
had no effect on these processes. Importantly, the uPA inhibitor
UK122 attenuated LMW-HA- and HABP2-dependent tumor cell
motion, migration, and transendothelial extravasation. Taken as a
whole, our data suggest that LMW-HA and HABP2 promote lung
cancer progression through uPA-regulated pathways (Figure 6).
We have previously reported that HABP2, though primarily
localized in the plasma, is upregulated in the lung endothe-
lium with LPS-induced ALI and in cultured human pulmonary
Frontiers in Oncology | www.frontiersin.org July 2015 | Volume 5 | Article 1648
Mirzapoiazova et al. HABP2 regulation of lung cancer
FIGURE 5 | Hyaluronan binding protein 2 promotes human lung
adenocarcinoma tumor growth and metastasis. (A) Graphical
representation tumor volume of vector control, HABP2 shRNA, and HABP2
overexpressing (O/E) SK-LU-1 cells embedded in Matrigel supplemented with
100 ng/ml HMW-HA or LMW-HA injected into the hind flank of nude mice for
30 days. The single asterisks (*) represents a statistically significant difference
(p<0.05) between control and HABP2 overexpressing (O/E) SK-LU-1
tumors. The double asterisks (**) represents a statistically significant difference
(p<0.05) between control and LMW-HA added SK-LU-1 tumors. The triple
asterisks (***) represents a statistically significant difference (p<0.05)
between control HABP2 overexpressing (O/E) tumors and LMW-HA added
HABP2 overexpressing (O/E) SK-LU-1 tumors. (B) Representative
immunoblot analysis of human SK-LU-1 NSCLC cells alone, control nude
mouse lung homogenate, lung homogenate from nude mouse with vector
control SK-LU-1 hind flank tumor or lung homogenates from nude mice with
HABP2 shRNA or HABP2 overexpressing (O/E) SK-LU-1 hind flank tumors
using anti-nestin or anti-actin antibodies. (C) Graphical representation of lung
metastasis from vector control or HABP2 overexpressing SK-LU-1 hind flank
tumors in nude mice using quantitation of nestin immunoreactivity as depicted
in (B). The asterisks (*) represents a statistically significant difference
(p<0.05) between HABP2 overexpressing (O/E) versus control or HABP2
shRNA with n= 5/group.
microvascular ECs (11). The enzymatic activity of HABP2 is
differentially regulated by hyaluronan (HA) with HMW-HA (the
main form of HA in vivo) inhibiting HABP2 protease activity,
HABP2
uPA
Lung Cancer Migra!on, Extravasa!on,
Tumor Growth and Metastasis
HMW-HA LMW-HA
FIGURE 6 | A proposed schematic diagram illustrating the role of HA
and HABP2 in lung cancer progression. High-molecular weight hyaluronan
(HMW-HA) inhibits, while low-molecular weight hyaluronan (LMW-HA)
promotes HABP2 (extracellular serine protease upregulated in lung cancer)
activity. Activated HABP2 can stimulate activation of urokinase plasminogen
activator (uPA), which is required for LMW-HA-mediated lung cancer
migration, transendothelial extravasation, tumor growth, and metastasis.
while LMW-HA (produced in disease states including cancer
via HMW-HA cleavage by hyaluronidase enzymes and ROS)
binds to the PABD of HABP2 and stimulates activity (11). Acti-
vatedHABP2 induces protease-activated receptor signaling in EC,
which leads to activation of the actin regulatory molecules RhoA
andROCKand endothelial barrier disruption. The barrier disrup-
tive role of HABP2 were further confirmed by vascular silencing
of HABP2 expression, which attenuated the vascular leakiness
observed in LPS- and ventilator-induced lung injury (11). In this
study, we have extended our findings to show that LMW-HA and
HABP2 contribute to lung cancer progression in an uPA-regulated
manner.
Hyaluronan binding protein 2 has been implicated in sev-
eral disease processes, including atherosclerosis, ALI/ARDS, deep
venous thrombosis, and cancer (3, 4, 6, 44). In addition, theG534E
mutation of HABP2 is associated with cardiovascular disease
and thromboembolism (45–47). However, the mechanism(s) by
which HABP2 contributes to disease processes remains elusive. In
normal blood coagulation cascade regulation, the role of HABP2
is complex since it activates factors involved in both coagulation
and fibrinolysis (5). Our data that HABP2 promote uPA activation
provides importantmechanistic insights intoHABP2 involvement
in diseases associated with vascular dysfunction including lung
cancer.
Identification of uPA as a target of HABP2 can have impor-
tant clinical consequences. uPA is a extracelluar serine protease
consisting of three domains, a serine protease domain, a kringle
domain, and a growth factor-like domain (48). uPA is synthesized
as a zymogen form and is activated by proteolytic cleavage by other
proteases including HABP2 (7). Activated uPA has several targets
including plasminogen and uPAR (49, 50). Recombinant uPA is
used clinically as a thrombolytic agent in the treatment of severe
deep venous thrombosis, pulmonary embolism, and myocardial
infarction (51–53). However, elevated levels of uPA and other
components of the plasminogen activation system are correlated
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with tumor malignancy (54). Through its interaction with uPAR,
uPA has been shown to promote cancer cell adhesion, migration,
and proliferation (55–59). These functions make uPA a potential
drug target in cancer. Currently, small molecule serine protease
inhibitors are being tested as a potential therapeutic strategy in
various cancer types (60).
We have also discovered a differential effect of HA on HABP2
and uPA-regulated lung cancer progression based on its molec-
ular weight. High levels of HA are observed in several types of
lung cancer and inhibition of HA synthesis reduces lung cancer
metastasis (12–17, 61, 62). Further, accumulation of LMW-HA is
correlated with cancer invasion and metastasis (63). In addition,
the enzymatic proteins to produce HMW-HA and LMW-HA
are upregulated in lung cancer including hyaluronan synthase 3
and hyaluronidase-1 (64). Although other HA-binding proteins
are upregulated in lung cancer including CD44, RHAMM, and
LYVE-1 (65–69); to the best of our knowledge, this is the first
report of a functional role of HABP2 in HA-mediated lung cancer
progression.
Given previous published data indicating HABP2 is increased
in lung cancer (3), we undertook a series of in vitro and in vivo
experiments to examine the direct effects of HABP2 in lung
cancer progression using human NSCLC cells. Our results indi-
cate that LMW-HA and HABP2 promote lung cancer onco-
genic properties. Importantly, our observations that HABP2
overexpression activates uPA suggest a potential therapeutic
advantage using combinational HABP2 and uPA inhibitors in
the treatment of NSCLC. Taken together, our data suggest a
possible direct effect of HABP2 overexpression on lung can-
cer progression, and provide a potential functional explanation
for the increased HABP2 expression observed in lung cancer.
Our observations further suggest a possible therapeutic role
for extracellular serine protease inhibitors, which merits further
evaluation.
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